 |
|
|
| |
Efficacy and Safety of Switching From Boosted Protease Inhibitor-based Regimens to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
for Treatment of HIV-1 Infection: Subgroups Analysis by Baseline Regimen
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
Pierre-Marie Girard,1 Gregory D. Huhn,2,* Edwin DeJesus,3 Donghan Luo,4 Romana Petrovic,5 Kimberley Brown,5 Eric Y. Wong6
1University Pierre and Marie Curie, Paris, France; 2The Ruth M. Rothstein CORE Center, Chicago, IL, USA; 3Orlando Immunology Center, Orlando, FL, USA; 4Janssen Research & Development, LLC, Titusville, NJ, USA; 5Janssen Research & Development, Beerse, Belgium; 6Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
|
| |
|
|
|
|
|
